Chemomab Therapeutics Stock (NASDAQ:CMMB)
Previous Close
$1.65
52W Range
$0.45 - $2.55
50D Avg
$1.57
200D Avg
$1.23
Market Cap
$31.11M
Avg Vol (3M)
$119.08K
Beta
0.30
Div Yield
-
CMMB Company Profile
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
CMMB Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| ZVSA | ZyVersa Therapeutics, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| BDRX | Biodexa Pharmaceuticals Plc |
| MNPR | Monopar Therapeutics Inc. |
| LEXX | Lexaria Bioscience Corp. |
| SABS | SAB Biotherapeutics, Inc. |
| CVKD | Cadrenal Therapeutics, Inc. Common Stock |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| ELDN | Eledon Pharmaceuticals, Inc. |
| RNXT | RenovoRx, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| CLRB | Cellectar Biosciences, Inc. |
| LUMO | Lumos Pharma, Inc. |